 This randomized study was designed to evaluate the efficacy and safety of IPu-infused liatermin 15mgputamenday compared with placebo in subjects with symptomatic, levodopa-response Parkinsons disease. This study consisted of a 90-day evaluation period followed by implantation of the IPu delivery system and then a 6-month double-blind treatment period. 